An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Prior treatment

• Prior systemic anti-cancer treatment (except surgery and interferon for thick primary melanomas. Radiotherapy after lymph node dissection is permitted)
• Live vaccine within 30 days prior to the first dose of pembrolizumab
• Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab
• Solid organ or allogeneic bone marrow transplant
• Prior interstitial lung disease

Other illness

• Prior malignancy, unless no evidence of that disease for at least 5 years prior to study entry
• Active autoimmune disease
• Pneumonitis or a history of (noninfectious) pneumonitis that required steroids
• Clinically significant heart failure
• Known history of human immunodeficiency virus (HIV)
• Known active hepatitis B or C
• Active infection requiring treatment

Other

• Transfusion of blood or administration of colony stimulating factors within 2 weeks of the screening blood sample

• Resectable cutaneous melanoma metastatic to a lymph node and at high risk of recurrence
• Complete resection within 13 weeks prior to the first dose of pembrolizumab
• Disease free at study entry (after surgery) with no loco-regional relapse or distant metastasis and no clinical evidence of brain metastases
• Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for sequencing
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
• Normal organ and marrow function reported at screening